Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04226365 · ClinicalTrials.gov registry record · Phase 4
Pediatric Concussion Outcomes
A Phase 4 study, sponsored by Lancaster General Hospital.
- Terminated
- Registry status
- Phase 4
- Development phase
- 8
- Enrollment target
NCT04226365 is a Phase 4 study that was terminated before completion, run by Lancaster General Hospital. The registered enrollment target is 8 participants.
The verdict
NCT04226365, a Phase 4 study, was terminated before completion, sponsored by Lancaster General Hospital.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 8 participants
- Enrollment target
Study Summary
This is a randomized, placebo-controlled, double-blinded trial in which subjects with a post concussive headache meeting inclusion criterion will be assigned to one of two treatment groups: placebo or nortriptyline. Each group will be evaluated at week 0 and again each week for the next 4 weeks of treatment with a concussion survey that rates their symptoms. At the end of 4 weeks the study will be unblinded. It is hypothesized that the addition of nortriptyline to the standard headache treatments will result in more rapid decrease of symptom score than with placebo.
Interventions
- DRUG Placebo
- DRUG Nortriptyline
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2020-02-15 |
| Est. Completion | 2023-05-31 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04226365
The ClinicalTrials.gov registry entry for NCT04226365 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Lancaster General Hospital, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04226365 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04226365 about?
NCT04226365 is a clinical study titled "Pediatric Concussion Outcomes". This is a randomized, placebo-controlled, double-blinded trial in which subjects with a post concussive headache meeting inclusion criterion will be assigned to one of two treatment groups: placebo or nortriptyline. Each group will be evaluated at week 0 and again each week for the next 4 weeks of t...
What is the current status of trial NCT04226365?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 8 participants. The study started on 2020-02-15. Estimated completion is 2023-05-31.
What interventions are being tested in trial NCT04226365?
The interventions under investigation include: Placebo (DRUG), Nortriptyline (DRUG).
Who is sponsoring clinical trial NCT04226365?
This trial is sponsored by Lancaster General Hospital, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.